Targeting CD47 has emerged as a promising strategy in cancer therapy. Anti-CD47 antibodies can block the interaction between CD47 and SIRPα, thereby promoting the phagocytosis of cancer cells. This approach has shown potential in preclinical studies and is currently being evaluated in clinical trials for various types of cancer, including leukemia, lymphoma, and solid tumors.
